随着肥胖、2型糖尿病等代谢性疾病的高发,GLP-1(胰高血糖素样肽-1)受体激动剂凭借优势成为医药领域的热门赛道。相较于传统注射剂型,口服GLP-1药物因便利性更受市场青睐,成为药企布局的核心方向。当前,国产口服GLP-1研发势头强劲,全球在研国产药物超20款,多款产品推进至临床关键阶段,部分实现海外授权突破,中国创新药企正逐步打破海外垄断,在市场中抢占先机。在国产口服GLP-1管线中,华东医药、...
Source Link随着肥胖、2型糖尿病等代谢性疾病的高发,GLP-1(胰高血糖素样肽-1)受体激动剂凭借优势成为医药领域的热门赛道。相较于传统注射剂型,口服GLP-1药物因便利性更受市场青睐,成为药企布局的核心方向。当前,国产口服GLP-1研发势头强劲,全球在研国产药物超20款,多款产品推进至临床关键阶段,部分实现海外授权突破,中国创新药企正逐步打破海外垄断,在市场中抢占先机。在国产口服GLP-1管线中,华东医药、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.